Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Marie Skłodowska-Curie Action · Running

MagBIO Living magnetobots for targeted theranostics to tackle metastatic solid tumours

Coordinator
Aston University, United Kingdom
Runs
1 June 2026 to 31 May 2030
Status
Running
EU funding
€1.2m
Total cost
—
Partners
18 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101299576

What the project is doing

In the project's own words, from its summary on CORDIS.

MagBIO (“Living magnetobots for targeted theranostics to tackle metastatic solid tumours”) is an interdisciplinary, international and intersectoral collaborative effort to develop living “magnetobots” technology that utilises the mechanism of personnel exchanges between 18 partners located in Europe and the USA to address socioeconomic and healthcare challenges. Through carefully planned and integrated secondments, MagBIO will use knowledge transfer to train 34 ESRs (early-stage) and 33 ERs (experienced researchers) to be future leaders in academia and industry.

The major problem that we shall tackle focuses on combining targeted therapies and diagnostic imaging (theranostic) technologies to identify and treat solid tumours of common cancers in Europe (pancreatic, breast, lung, colorectal), embracing sustainability and safety aspects from early-stage MedTech development. MagBIO is conceived to design, test, and disseminate sustainable ground-breaking theranostic technology into a single platform inspired by microorganisms that naturally sense magnetic fields and thrive in hypoxic environments such as cancer tumours.

To this end, magnetotactic bacteria will be engineered for targeted delivery of payloads, addressing unmet needs to tackle metastatic solid tumours. The key to achieving this lies in the interdisciplinary and cross-sectorial nature of the consortium to develop the next generation of sustainable and personalised medicines to improve the quality of life of people in the EU and beyond, whilst contributing to a sustainable medicines biomanufacturing industry.

Topics

Who is involved

OrganisationCityCountryRole
Aston UniversityBirminghamUnited KingdomCoordinator
Nanotechnology Industries AssociationBruxelles / BrusselBelgiumParticipant
Magnebotix AGZurichSwitzerlandAssociatedpartner
Aeris Tecnologias Ambientales SLCerdanyola Del VallesSpainParticipant
Universidad De GranadaGranadaSpainParticipant
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainParticipant
Universitat Autonoma De BarcelonaCerdanyola Del VallesSpainParticipant
Commissariat a L Energie Atomique Et Aux Energies AlternativesParisFranceParticipant
Institut Za Medicinska Istrazivanja I Medicinu RadaZagrebCroatiaParticipant
Alma Mater Studiorum - Universita Di BolognaBolognaItalyParticipant
Renuvait S R LSan Giovanni LupatotoItalyParticipant
Latvijas UniversitateRigaLatviaParticipant
Diamond Light Source LimitedDidcotUnited KingdomParticipant
Europe for Business LtdManchesterUnited KingdomParticipant
EVolution Therapeutics LTDCoventryUnited KingdomAssociatedpartner
Polymodels Hub LtdLondonUnited KingdomAssociatedpartner
The University of SheffieldSheffieldUnited KingdomParticipant
Oamuru BioSystemsLoganUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI